NCT06632912 2026-01-23Phase IIIb Clinical Trial of Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) for Age/Immunization Schedule BridgingNational Vaccine and Serum Institute, ChinaPhase 3 Active not recruiting1,800 enrolled